Use of tobramycin in eradicating experimental bacterial endophthalmitis.
D000617:Aminoglycosides / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D001082:Aqueous Humor; D002386:Cataract / Q000139:chemically induced; D003228:Conjunctiva; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005123:Eye / Q000473:pathology; D005128:Eye Diseases / Q000188:drug therapy* / Q000473:pathology; D007267:Injections; D007273:Injections, Intramuscular; D007500:Iritis / Q000139:chemically induced; D009887:Ophthalmoscopy; D010636:Phenols / Q000008:administration & dosage / Q000633:toxicity; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000473:pathology; D011550:Pseudomonas aeruginosa; D011817:Rabbits; D012162:Retinal Degeneration / Q000139:chemically induced; D013431:Sulfates / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D013997:Time Factors; D014822:Vitreous Body / Q000378:metabolism; D014946:Wound Infection / Q000188:drug therapy* / Q000473:pathology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010636:Phenols; D013431:Sulfates